KMT2A and acute myeloid leukemia: The presence of genetic aberrations, such as FLT3, NPM1 mutations, and MLL-AF9 gene fusion, are pivotal in predicting the prognosis, relapse, and therapeutic responses in AML, emphasizing the crucial role of personalized medicine in its management.